Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia
- PMID: 25895602
- DOI: 10.1159/000371831
Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia
Abstract
We report on the emergence and clinical relevance of an unusual BCR-ABL1 kinase domain mutational status in a 2-year-old female with p210-BCR-ABL Philadelphia chromosome-positive acute lymphoblastic leukaemia. We detected three BCR-ABL1 clones determined by the presence of the E255V, D276G and F317L mutations. We point out the usefulness of searching for mutated populations that survive tyrosine-kinase inhibitor therapy and the role of their clonal selection over time in relation to therapeutic intervention.
© 2015 S. Karger AG, Basel.
Comment in
-
BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?Acta Haematol. 2015;134(2):69-70. doi: 10.1159/000380874. Epub 2015 Apr 18. Acta Haematol. 2015. PMID: 25895547 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous